No abstract

We do not appreciate a significant relationship between 25 (OH) D3 levels and glucose control or OPF. Therefore, more studies are needed to identify the specific effect of 25 (OH) D3 in T2DM physiopathology.

Introduction Recurrence of papillary thyroid carcinoma after initial treatment is challenging. Surgical reintervention is recommended, but cure after surgery in uncertain and surgical morbidity may be high. This study evaluates the effect of compartment‐oriented lymph node dissection (LND) on clinical and biochemical cure rate as well as the related complications. Patients and methods All patients who underwent LND for recurrent papillary thyroid carcinoma between 2000 and 2015 were included. Demography, the extent of the initial surgery, usage of 131I, the pattern of recurrence, diagnosis, details of the surgical reintervention, histological findings, surgical morbidity, and clinical and biochemical outcomes were analyzed. Results There were 11 (12.7%) males and 75 (87.2%) females with a mean age of 42.8 ± 14.6 years. Seventy‐seven patients had undergone total thyroidectomy and in 67 (77.9%) some type of LN resection. In 76 (88.3%), 131I was administered after the initial surgery. We localized suspicious lymph nodes by US in all patients, and metastases were documented before surgery by FNA in 63. Seven (8.13%) patients underwent central LND, 63 (73.2%) lateral LND and 16 (18.6%) both, central and lateral LND. Major complications occurred in 6 patients (6.9%). Sixty‐two (72.0%) patients received 131I after surgery. A second surgical re‐exploration was performed in 30 (34.8%) patients, and 7 patients required 3 or more additional LND. In a mean follow‐up of 59.4 ± 39 months, 51 (59.3%) patients are clinically, radiologically and biochemically free of disease. Conclusions In this series, compartment‐oriented lymph node resection of recurrent papillary thyroid carcinoma leads to a final clinical and biochemical disease‐free status of 59.3% with 6.9% of major complications.

Head and neckClinical utility of an ultrasensitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer: can the stimulation test be avoided in patients with an intermediate recurrence risk?Utilità clinica del dosaggio ultrasensibile della tireoglobulina nel follow-up dei pazienti con carcinoma differenziato della tiroide: il test di stimolazione potrebbe essere evitato nei pazienti con rischio di recidiva intermedio?

No abstract